Evaluation of the efficacy and safety of intravitreal injection of ranibizumab every other month for age-related macular degeneration
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 05 Dec 2017 Status changed from recruiting to completed.
- 16 May 2017 According to UMIN, the date for data entry closure is 30-Jun 2018, and the date for conclusion of data analysis is 30-Jun 2019.
- 05 Dec 2015 New trial record